Leonard M. Azzarano

Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic

William H. Miller, Doreen Alberts, Pradip K. Bhatnagar et al. · Journal of Medicinal Chemistry · 1999 · 116 citations · Full text

Pharmacotherapy, Experimental Pharmacology, Pharmacodynamic Modeling +16

Preclinical Pharmacokinetic Properties of the P-Glycoprotein Inhibitor GF120918A (HCl salt of GF120918, 9,10-Dihydro-5-methoxy-9-oxo-N-[4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]phenyl]-4-acridine-carboxamide) in the Mouse, Rat, Dog, and Monkey

Keith W. Ward, Leonard M. Azzarano · Journal of Pharmacology and Experimental Therapeutics · 2004 · 63 citations

Design and synthesis of orally bioavailable serum and glucocorticoid-regulated kinase 1 (SGK1) inhibitors

Marlys Hammond, David G. Washburn, Tram H. Hoang et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 43 citations · Full text

Bioavailable Serum, Medicinal Chemistry, Pharmaceutical Science +11

DEVELOPMENT OF AN IN VIVO PRECLINICAL SCREEN MODEL TO ESTIMATE ABSORPTION AND FIRST-PASS HEPATIC EXTRACTION OF XENOBIOTICS. II. USE OF KETOCONAZOLE TO IDENTIFY P-GLYCOPROTEIN/CYP3A-LIMITED BIOAVAILABILITY IN THE MONKEY

Keith W. Ward, Gary J. Stelman, Jayme A. Morgan et al. · Drug Metabolism and Disposition · 2004 · 43 citations

Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens

Cherng‐Yih Perng, Albert S. Kearney, Nagesh R. Palepu et al. · International Journal of Pharmaceutics · 2002 · 40 citations

Oral Bioavailability, Oral Cavity, Pharmaceutical Technology +2